Biochemical and molecular markers in renal cell carcinoma: An update and future prospects

Biomarkers

Volumn 10, Issue 4, 2005, Pages 258-294

  Kashyap, Manoj K ^a   Kumar, A ^c   Emelianenko, N ^d   Kashyap, A ^e   Kaushik, R ^f   Huang, R ^a   Khullar, M ^b   Sharma, S K ^b   Singh, S K ^b   Bhargave, A K ^e   Upadhyaya, S K ^e  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c SAFDARJUNG HOSPITAL CAMPUS   (India)

^d DUBNA STATE UNIVERSITY   (Russian Federation)

^e CH CHARAN SINGH UNIVERSITY   (India)

^f M D S UNIVERSITY   (India)

Author keywords

Ferritin; iNOS; Kidney; Microsatellite markers; MN CA9; p75; Prognostic marker; Prognostic value; Renal cell carcinoma; Reverse transcription polymerase chain reaction (RT PCR)

Indexed keywords

AE 941; ANTINEOPLASTIC AGENT; APROTININ; CARCINOEMBRYONIC ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; EPHRIN RECEPTOR A2; FAS ANTIGEN; FERRITIN; FLUOROURACIL; HERMES ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; KI 67 ANTIGEN; NEOPTERIN; NEURON SPECIFIC ENOLASE; NUCLEAR MATRIX PROTEIN 22; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PYRUVATE KINASE; THYMIDYLATE SYNTHASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CLASSIFICATION; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; ERYTHROCYTE SEDIMENTATION RATE; GENE MUTATION; GENE OVEREXPRESSION; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; NEPHRECTOMY; NICK END LABELING; NONHUMAN; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TREATMENT FAILURE; TUMOR VOLUME;

ADULT; ANTIGENS, NEOPLASM; APOPTOSIS; BLOOD SEDIMENTATION; CARCINOMA, RENAL CELL; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FERRITINS; FORECASTING; GENOMICS; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; NEOPTERIN; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 26844531391     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500500218534     Document Type: Review

References (160)

1. Adcock IM, Shirasaki H, Gelder CM, Peters MJ, Brown CR, Barnes PJ. 1994. The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sciences 55:1147-1153.
2. Alexandrova R, Mileva M, Zvetkova E. 2001. Nitric oxide and cancer. Experimental Pathology and Parasitology, Bulgarian Academy of Sciences, 4-7.
3. American Joint Committee on Cancer. 1997. Kidney. In: AJCC cancer staging manual, 5th Edn. Philadelphia, PA: Lippincott-Raven. p. 231-234.
4. Batist G, Patenaude FP, Champagne D, Croteau C, Levinton C, Hariton Escudier B, Dupont E. 2002. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Annals of Oncology 13:1259-1263.
5. Beg AA, Finco TS, Nantermet PV, Baldwin AJ. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκB-α: a mechanism for NF-κB activation. Molecular Cell Biology 13:3301-3310.
6. Bjorklund B. 1978. Tissue polypeptide antigen (TPA): biology biochemistry, improved assay methodology, clinical significance in cancer and other conditions and future outlook. In: Schonfeld H, editor. Laboratory testing for cancer, antibiotics, and chemotherapy. Vol. 2. Basel: Karger. p. 16-31.
7. Boivin D, Gendron S, Beaulieu E, Ginggras D, Beliveau R. 2002. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Molecular Cancer Therapy 1:795-802.
8. Burt AD, Stewart JA, Aitchison M. 1987. Expression of tissue polypeptide antigen (TPA) in fetal and adult liver: changes in liver diseases. Journal of Clinical Pathology 40:719-724.
9. Bussolati B, Russo S, Deambrosis I, Cantaluppi V, Volpe A, Ferrando U, Camussi G. 2002. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. International Journal of Cancer 100:654-661.
10. Cairns P, Tokino K, Eby Y, Sidransky D. 1995. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Research 155:224-227.
11. Chang CH, Wu HC, Yen RF, Kao A, Lin CC. 2002. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma. Anticancer Research 22:2949-2950.
12. Chapman RS, Chresta CM, Herberg AA, Beere HM, Heer S, Whetton AD, Hickman JA, Dive C. 1995. Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Cytometry 20:245-256.
13. Charriaut-Marlangue C, Ben-Ari J. 1995. A cautionary note on the use of the TUNEL stain to determine apoptosis. Neuroreport 7:61-64.
14. Chudek J, Wilhelm M, Bugert P, Herbers J, Kovacs G. 1997. Detailed microsatellite analysis of chromosome 3p region in non-papillary renal cell carcinomas. International Journal of Cancer 73:225-229.
15. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. 2003. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biology 22:533-540.
16. Clark J, Lu YJ, Sridhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J, Cooper CS. 1997. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TEF3 gene in papillary renal cell carcinoma. Oncogene 15:2233-2239.
17. Cooper JA, Hunter T. 1983. Regulation of cell growth and transformation by tyrosine-specific protein kinases: the search for important cellular substrate proteins. Current Topics in Microbiology and Immunology 107:125-161.
18. Copland JA, Luxon BA, Ajani L, Maity T, Campagnaro E, Guo H, Legrand SN, Tamboli P, Wood CG. 2003. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene 22:8053-8062.
19. Dallmann K, Junker H, Balabanov S, Zimmermann U, Giebel J, Walther R. 2004. Human agmatinase is diminished in the clear cell type of renal cell carcinoma. International Journal of Cancer 108:342-347.
20. Dawson NA, Barr CF, Alving BM. 1985. Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. American Journal of Medicine 78:682-686.
21. Deguchi M, Shiina H, Igawa M, Kaneuchi M, Nakajima K, Dahiya R. 2003. DNA mismatch repair genes in renal cell carcinoma. Journal of Urology 169:2365-2371.
22. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. 2001. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Human Pathology 32:590-595.
23. Didenko VV, Hornsby PJ. 1996. Presence of double-stranded breaks with single-base 3′ overhang sin cells undergoing apoptosis but not necrosis. Journal of Cell Biology 135:1369-1376.
24. Ditsworth D, Zong WX. 2004. NF-kappa B: key mediator of inflammation-associated cancer. Cancer Biology Therapy 3:1214-1216.
25. Doherty NS, Littman BH, Reilly K, Swindell AC, Buss JM, Anderson NL. 1998. Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis. Electrophoresis 19:355-363.
26. Emelianenko NG. 2005. Latest news in theory of cancer-modern analysis. Strategy for war on cancer. Unpublished, April.
27. Engleman EG. 2003. Dendritic cell-based cancer immunotherapy. Seminars in Oncology 30:23-29.
28. Frankfurt OS, Krishan A. 2001a. Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. Journal of Histochemistry and Cytochemistry 49:369-378.
29. Frankfurt OS, Krishan A. 2001b. Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application for rapid drug screening. Journal of Immunology Methods 253:133-144.
30. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L. 1997. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases. Clinical Cancer Research 3:465-471.
31. Fuhrman S, Lasky C, Limas C. 1982. Prognostic significance of morphologic parameters in renal cell carcinoma. American Journal of Surgical Pathology 6:655-663.
32. Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F. 1999. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. British Journal of Cancer 80:407-411.
33. Gattinoni L, Alu M, Ferrari L, Nova P, Del Vecchio M, Procopio G, Laudani A, Agostara B, Bajetta E. 2003. Renal cancer treatment: a review of the literature. Tumori 89:476-484.
34. Gerharz CD, Ramp U, Dejosez M, Mahotka C, Czarnotta B, Bretschneider U, Lorenz I, Muller M, Krammer PH, Gabbert HE. 1999. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Laboratory Investigation 79:1521-1534.
35. Gilcrease MZ, Guzman-Paz M, Niehans G, Cherwitz D, McCarthy JB, Albores-Saavedra J. 1999. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 86:2320-2326.
36. Gingras D, Batist G, Beliveau R. 2001. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Reviews in Anticancer Therapy 1:341-347.
37. Girolami F, Passerini I, Gargano D, Frusconi S, Villari D, Nicita G, Torricelli F. 2002. Microsatellite analysis of chromosome 3p region in sporadic renal cell carcinomas. Pathology and Oncology Research 8:241-244.
38. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. 2002. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Investigation 20:324-332.
39. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. 2000. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037-1053.
40. Grady B, Goharderakhshan R, Chang J, Ribeiro-Filho LA, Perinchery G, Franks J, Presti J, Carroll P, Dahiya R. 2001. Frequently deleted loci on chromosome 9 may harbor several tumor suppressor genes in human renal cell carcinoma. Journal of Urology 166:1088-1092.
41. Grankvist K, Ljunberg B, Rasmuson T. 1999. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. International Journal of Cancer 74:233-236.
42. Grasl-Kraipp B, Ruttkau-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. 1995. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis and autolytic cell death: a cautionary note. Hepatology 21:1465-1468.
43. Gupta PK, Varshney RK. 2000. The development and use of microsatellite markers for genetic analysis and plant breeding with emphasis on bread wheat. Euphytica 113:163-185.
44. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. 1999. Expression of the cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosis. International Journal of Cancer 84:225-233.
45. Hara N, Bilim V, Kasahara T, Obara K, Saito K, Takahashi K, Tomita Y. 2003. Inducible nitric oxide, synthase in renal cell carcinoma: expression in tumor thrombi and induction under hypoxic conditions. Anticancer Research 23:4641-4649.
46. Hedborg Y, Davoodi E, Ljunberg B, Roos G, Lindberg G. 2002. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. International Journal of Cancer 102:601-607.
47. Hedman H, Nilsson J, Guo D, Henriksson R. 2002. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncologica 41:352-354.
48. Hegle A, Varga Z, Kosche B, Stief T, Heidenreich A, Hofmann R. 2003. Pyruvate kinase type tumor M2 in urological malignancies. Urology International 70:55-58.
49. Heider KH, Ratschek M, Zatloukal K, Adolf GR. 1996. Expression of CD44 isoforms in human renal cell carcinomas. Virchows Archiv 428:267-273.
50. Herbers J, Schullersu D, Muller H, Kenck C, Chudek J, Weimer J, Bugert P, Kovacs G. 1997. Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Genes Chromosomes and Cancer 19:29-35.
51. Herbert V, Jayatilleke E, Shaw S, Rosman AS, Giardina P, Grady RW, Bowman B, Gunter EW. 1997. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 15:291-296.
52. Hibbs JB Jr, Westenfelder C, Taintor R, Vavrin Z, Kablitz C, Baranowski RL, Ward JH, Menlove RL, McMurry MP, Kushner JP, et al. 1992. Evidence for cytokine-inducible nitric oxide synthesis from Larginine in patients receiving interleukin-2 therapy. Journal Clinical Investigation 89:867-877.
53. Hoffmann R, Valencia A. 2004. A gene network for navigating the literature. Nature Genetics 36:664.
54. Hofmockel G, Tsatalpas P, Muller H, Dammrich J, Poor M, Maurer-Schultze B, Muller-Hermelink HK, Frohmuller HG, Bassukas ID. 1995. Significance of conventional and new prognostic factors for locally confined renal cell carcinoma. Cancer 76:296-306.
55. Honda K, Ohga S, Takada H, Nomura A, Ohshima K, Kinukawa N, Mizuno Y, Hara T. 2000. Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation. International Journal of Hematology 72:55-60.
56. Horoszewicz JS, Kawinski E, Murphy G. 1987. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Research 7:927-935.
57. Huang A, Fone PD, Gandour-Edwards R, White RW, Low RK. 1999. Immunohistochemical analysis of BCL-2 protein expression in renal cell carcinoma. Journal of Urology 162:610-613.
58. Iversen OH, Roeger M, Solberg HE, Wetteland P. 1998. Rising erythrocyte sedimentation rate during several years before diagnosis can be a predictive factor in 70% of renal cell carcinoma patients. Journal of Internal Medicine 240:133-141.
59. Iwagaki H, Hizuta A, Tanaka N, Orita K. 1995. Plasma neopterin/C-reactive protein ratio as an adjunct to the assessment of infection and cancer cachexia. Immunology Investigation 24:479-487.
60. Itoi T, Yamana K, Bilim V, Takahashi K, Tomita F. 2004. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. British Journal of Cancer 90:200-205.
61. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Guido S, Mihatsch MJ, Holger M. 1998. Genetic differences between histological subtypes. Chromosomal imbalances in papillary renal cell carcinoma. American Journal of Pathology 153:1467-1473.
62. Johnson R, Brown E. 2000. Cell-mediated immunity in host defense against infectious diseases. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone. p. 112-146.
63. Jung SM, Kuo TT. 2005. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Modern Pathology 18:788-794.
64. Kallfelz M, Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. 1999. Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer. International Journal of Cancer 81:125-133.
65. Kamihira S, Yamada Y. 2001. Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia. Leukemia and Lymphoma 41:169-176.
66. Kashyap MK. 2003. MN/CA9 Gene expression as a potential biomarker in renal cell carcinoma, In: P-91. CDC Cancer Conference, Atlanta, GA, USA.
67. Kashyap MK, Kumar A, Kaushik G, Sharma PC, Khullar M. 2003. Role of bio-informatics in molecular medicine. In: Conference at Scuola Superiore G. Reiss Romoli (SSGRR) Rome, Italy (available at: http://www.ssgrr.it/en/ssgrr.2003w/papers/193.pdf) (accessed on 1 February 2005).
68. Kashyap MK, Singh SK, Singh K, Khullar M, Sharma SK. 2003. Role of an iron protein (Ferritin) as a prognostic marker in renal cell carcinoma. Transactions of the Illinois State Academy of Sciences 96:S62-S63.
69. Keeton WT, Gould JL, Gould CG. 1986. Biological science. 4th Edn. New York: W. W. Norton. p. 762.
70. Kikuchi H. 2004. Tumor markers of urinary tract carcinoma. Rinsho Byori 52:371-380. [in Japanese]
71. Kirkali Z, Guzelzoy M, Mungan MU, Kirkali G, Yorukoglu K. 1999. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume. Urology International 62:21-25.
72. Kralj M, Pavelic J. 2003. p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo. Journal of Cancer Research Clinical Oncology 129:463-471.
73. Kuiper RP, Schepens M, Thijssen J, Van Asseldonk M, Van Den Berg E, Bridge J, Schuuring E, Schoenmakers EF, Van Kessel AG. 2003. Up-regulation of the transcription factor TFEB in t(6; 11) (p21; q13)-positive renal cell carcinomas due to promoter substitution. Human Molecular Genetics 12:1661-1669.
74. Kuroda N, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Moriki T, Yamasaki Y, Numoto S, Yamamoto Y, et al. 2000. Vinculin: its possible use as a marker of normal collecting ducts and renal neoplasmas with collecting duct system phenotype. Modern Pathology 13:1109-1114.
75. Leach FS, Koh M, Sharma K, McWilliams G, Talifero-Smith L, Codd A, Olea R, Elbahloul O. 2002. Mismatch repair gene mutations in renal cell carcinoma. Cancer Biology and Therapy 1:530-536.
76. Lee CC, Masuda C, Yamamoto S, Wanibuchi H, Ikemoto S, Sugimura K, Nakatani T, Wada S, Kishimoto T, Fukushima S. 1998. Assessment of cell cycle-related elements p53, p21WAF1/Cip1, cyclin D1 and PCNA in a mixed transitional cell carcinoma and adenocarcinoma of the renal pelvis: a case report. Japanese Journal of Clinical Oncology 28:227-232.
77. Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishimoto T, Fukushima S. 1997. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 79:780-789.
78. Lee CT, Genega EM, Hutchinson B, Fearn PA, Kattan MW, Russo P, Reuter VE. 2003. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors. Urology and Oncology 21:179-184.
79. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. 1997. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Research 57:2827-2831.
80. Lichtenfels R, Kellner R, Atkins D, Bukur J, Ackermann A, Beck J, Brenner W, Melchior S, Seliger B. 2003. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochimica et Biophysica Acta 1646:21-31.
81. Liggett WH Jr, Sidransky D. 1998. Role of the p16 tumor suppressor gene in cancer. Journal of Clinical Oncology 16:1197-1206.
82. Ling WP, Rayman R, Uzzo P, Clark HJ, Kim HJ, Tubbs R, Novick A, Bukowski R, Hamilton T, Finke J. 1998. Impaired activation of NFk B in T-cells from renal cell carcinoma patients in mediated by inhibition of phosphorylation and degradation of the inhibitor Ik Ba. Blood 91:1334-1341.
83. Liou LS, Shi T, Duan ZH, Sadhukhan P, Der SD, Novick AA, Hissong J, Skacel M, Almasan A, DiDonato JA. 2004. Microarray gene expression profiling and analysis in renal cell carcinoma. BioMed Central Urology 4:9.
84. Lipponen P. 1999. Apoptosis in breast cancer: relationship with other pathological parameters. Endocrine and Related Cancers 6:13-16.
85. Ljunberg B, Grankvist K, Rasmuson T. 1997. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. European Journal of Cancer 33:1794-1798.
86. Malhi S, Jawde RA, Merhi GB, Mekhail T, Raymon P, Messerli EC, Elson P, Olencki T, Finke JH, Bukowski, RM. 2002. NF-κB expression in peripheral blood T-cells (T-PBL) of metastatic renal cell cancer (RCC) patients: clinical and pathological correlation. In: Cleveland Clinic Foundation Cleveland, OH, USA, 2002 ASCO Annual Meeting, abstract 760.
87. Mantur M, Kemona H, Pietruczuk M, Wasiluk A. 2002. Does renal carcinoma affect the expression of P-selectin on platelets? Neoplasma 49:243-245.
88. Mata MT, Lohr M, Lakshminarayanan K, Lo H, Prabhakar U. 2004. Serum amyloid A (SAA), C-reactive protein (CRP) and IL-6 as prognostic indicators in renal cell carcinoma and prostate cancer. Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22:9711.
89. McCue PA, Gorstein F. 2001. Genetic markers in renal cell carcinomas. Human Pathology 32:1027-1028.
90. Medeiros LJ, Gelb AB, Weiss LM. 1988. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 61:1639-1651.
91. Mejean A, Oudard S, Thiounn N. 2003. Prognostic factors of renal cell carcinoma. Journal of Urology 169:821-827.
92. Meria P, Toubert ME, Cussenot O, Bassi S, Janssen T, Desgrandchamps F, Cortesse A, Schlageter MH, Teililac P, Duc AL. 1995. Tumour-associated trypsin inhibitor and renal cell carcinoma. European Journal of Urology 27:223-226.
93. Miyanaga N. 1997. Clinical evaluation of NMP-22 in urine as a novel marker for urothelial cancer. European Urology 31:163-168.
94. Mizutani Y, Wada H, Osamu Y, Masakazu F, Mitsuo N, Masahiro N, Tsuneharu M. 2003. Significance of thymidylate synthase activity in renal cell carcinoma. Clinical Cancer Research 9:1453-1460.
95. Modrich P. 1991. Mechanisms and biological effects of mismatch repair. Annual Reviews of Genetics 25:229-253.
96. Motzer RJ, Bander NH, Nanus DM. 1996. Renal-cell carcinoma. New England Journal of Medicine 335:865-875.
97. Mufti GJ, Hamblin TJ, Stevens J. 1982. Basic isoferritin and hypercalcaemia in renal cell carcinoma. Journal of Clinical Pathology 35:1008-1010.
98. Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S. 1999. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. British Journal of Urology International 83:743-747.
99. Nagy A, Balint I, Kovacs G. 2003. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. International Journal of Cancer 106:980-981.
100. Opavsky R, Pastorekova S, Zelink V, Gibadulnova A, Stanbridge EJ, Zavada J, Kettmann R, Pastorek J. 1996. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33:480-487.
101. Ordonez NG. 2004. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Human Pathology 35:697-710.
102. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. 2002. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology 60:593-597.
103. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. 1994. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78:773-785.
104. Pantuck AJ, Zisman A, Belldegrun A. 2001. Biology of renal cell carcinoma: changing concepts in classification and staging. Semin Urol Oncol 19:72-79.
105. Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML. 2003. Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. Journal of Urology 170:420-424.
106. Paul R, Ewing CM, Robinson JC, Marshall FF, Johnson KR, Wheelock MJ, Isaacs WB. 1997. Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Research 57:2741-2748.
107. Pich A, Chiusa L, Margaria E. 1995. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis. Cancer Detection and Prevention 19:282-291.
108. Pich A, Valente G, Azzoni L, Stramignoni A, Margaria E, Tasso M. 1991. Argyrophilic nucleolar organizer region counts and Ki-67 scores in human renal cell carcinoma. Pathology Research and Practice 187:482-486.
109. Ploton D, Menager M, Jeannesson P, Himbler G, Pigeon F, Adnet JJ. 1986. Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochemistry Journal 18:5-14.
110. Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R, Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, et al. 1999. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this 'adaptive response' in mice. Clinical Pharmacology and Therapy 65:615-629.
111. Reed JC. 1998. Bcl-2 family proteins. Oncogene 17:3225-3236.
112. Richter EN, Oevermann K, Buentig N, Storkel S, Dallmann I, Atzpodien J. 2002. Primary apoptosis as a prognostic index for the classification of metastatic renal cell carcinoma. Journal of Urology 168:460-464.
113. Rifai N, Ridker PM. 2003. Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clinical Chemistry 49:666-669.
114. Robson CJ, Churchill BM, Anderson W. 1969. The results of radical nephrectomy for renal cell carcinoma. Journal of Urology 101:297-301.
115. Romanenko A, Morell-Quadreny L, Lopez-Guerrero JA, Pellin A, Nepomnyaschy V, Vozianov A, Llombart-Bosch A. 2002. P16INK4A and p15INK4B gene alteration associated with oxidative stress in renal cell carcinomas after the Chernobyl accident (pilot study). Diagnostic and Molecular Pathology 11:163-169.
116. Rossner P, Boffetta P, Ceppi M, Bonassi S, Smerhovsky Z, Landa K, Juzova D, Sram RJ. 2005. Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer. Environmental Health Perspectives 113:517-520.
117. Rüdiger M. 1998. Vinculin and alpha-catenin: shared and unique functions in adherens junctions. Bioessays 20:733-740.
118. Rydlander L, Ziegler E, Bergman T, Schoberl E, Steiner G, Bergman AC, Zetterberg A, Marberger M, Bjorklund P, Skern T, et al. 1996. Molecular characterization of a tissue polypeptide specific antigen epitope and its relationship to human cytokeratin 18. European Journal of Biochemistry 241:309-314.
119. Sanz-Casla MT, Maestro ML, Del Barco V, Zanna I, Moreno J, Vidaurreta M, Almansa I, Fernandez C, Blanco J, Maestro C, Resel L. 2003. Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urology Research 31:159-162.
120. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. 1992. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proceedings of the National Academy of Sciences USA 89:12160-12164.
121. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ. 1997. Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their up-regulation by IFN-gamma. Scandinavian Journal of Immunology 46:625-632.
122. Seliger B, Menig M, Lichtenfels R, Atkins D, Bukur J, Haldar TM, Kersten M, Harder A, Ackermann A, Beck J, et al. 2003. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy. Proteomics 3:979-990.
123. Seripa D, Parrella P, Gallucci M, Gravina C, Papa S, Fortunato P, Alcini A, Flammia G, Lazzari M, Fazio VM. 2001. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. International Journal of Cancer 95:364-369.
124. Shalitin C, Epelbaum R, Moskovitz B, Segal R, Valansi C, Werner M, Livne PM. 1994. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients. Cancer Detection and Prevention 18:357-365.
125. Sheldon J, Riches PG, Soni N, Jurges E, Gore M, Dadian G, Hobbs JR. 1991. Plasma neopterin as an adjunct to C-reactive protein in assessment of infection. Clinical Chemistry 37:2038-2042.
126. Shi T, Dong F, Liou LS, Duan ZH, Novick AC, Didonato JA. 2004. Differential protein profiling in renal-cell carcinoma. Molecular Carcinogenesis 40:47-61.
127. Shim Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M, Soo Park C. 2003. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. Journal of Surgical Oncology 84:166-172.
128. Shimazui T, Akaza H. 2004. Significance of current bio- and molecular-markers in urological cancers. Gan To Kagaku Ryoho 31:1008-1014. [in Japanese]
129. Shin KH, Park YJ, Park JG. 2001. PTEN gene mutations in colorectal cancers displaying microsatellite instability. Cancer Letters 174:189-194.
130. Steffens MG, Boerman OC, De Mulder PH, Oyen WJWC, Witjes JA, Van Den Broekk WJ, Oosterwijk-Wakka JC, Debruyne FM, Corstens FH, Oosterwijk E. 1999. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clinical Cancer Research 5:3268-3274.
131. 131I-labeled chimeric monoclonal antibody G250. Clinical Cancer Research 5:3268-3274.
132. Syrigos KN, Karapanagiotou E, Harrington KJ. 2004. The clinical significance of molecular markers to bladder cancer. Hybrid Hybridomics 23:335-342.
133. Takashi M, Haimoto H, Tanaka J, Murase T, Kato K. 1989. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma. Journal of Urology 141:830-834.
134. Takashi M, Sakata T, Kato K. 1993. Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma. Japanese Journal of Cancer Research 84:304-309.
135. Tatsumi T, Herrem. CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ. 2003. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Research 63:4481-4489.
136. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, Gunthert U. 1996. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. American Journal of Pathology 148:453-463.
137. Thomas D, Maniatis T. 1995. NF-κB: a lesson in family values. Cell 80:529-532.
138. Thomasson M, Hedman H, Guo D, Ljunberg B, Henriksson R. 2004. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. British Journal of Cancer 89:1285-1289.
139. Tong AW, Stone MJ. 2003. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Therapy 10:1-13.
140. Tsakalou G, Tamvakis N, Dimopoulos MA. 2003. Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. Urology 62:368-373.
141. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. 2002. Gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine 347:1999-2009.
142. Van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
143. Volankis J. 1997. Acute phase proteins in rheumatic disease. In: Koopman W, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore, MD: Williams & Wilkins. p. 505-514.
144. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB. 1991. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Research 51:2720-2726.
145. Weiss RB, Greene RF, Knight RD, Collins JM, Pelosi JJ, Sulkes A, Curt GA. 1988. Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Research 48:5878-5882.
146. Westenfelder C, Baranowski RL. 2000. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney International 58:647-657.
147. Wiseman GA, Scott AM, Lee FT. 2001. Chimeric G250 (cG250) monoclonal antibody Phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology, abstract 1027.
148. Wu Z, Zhang Y, Liu D. 1997. [Diagnostic value of CD44 splice variants in urine exfoliated cells of bladder cancer] [Article in Chinese]. Zhonghua Wai Ke Za Zhi 35:533-535.
149. Xie K, Dong Z, Fidler IJ. 1996. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. Journal of Leukocyte Biology 59:797-803.
150. Xie K, Fidler IJ. 1998. Gene therapy with the inducible nitric oxide synthase for induction of apoptosis to control tumor growth and metastasis. Cancer Metastasis Reviews 17:55-75.
151. Xie K, Huang S. 2003. Contribution of Nitric oxide-mediated apoptosis to cancer. Free Radical Biology and Medicine 34:969-986.
152. Xie QW, Kashiwabara Y, Nathan C. 1994. Role of transcription factor NF-kappa B/Re1 in induction of nitric oxide synthase. Journal of Biology and Chemistry 269:4705-4708.
153. Xu W, Liu L, Charles IG, Moncada S. 2004. Nitric oxide induces coupling of mitochondrial signaling with the endoplasmic reticulum stress response. Nature Cell Biology 6:1129-1134.
154. Yamout AN, Kashyap MK, Spec A, Rochlin MW. 2003. Differential response to neurotrophic factors and neuropilins may contribute to sensory nerve divergence. In: Program No. 887.7. New Orleans, LA: Society for Neuroscience.
155. Yao M, Yoshida M, Kishida T, Nakagawa N, Baba M, Kobayashi K, Miura T, Moriyama M, Nagashima Y, Nakatani Y, Kubota Y, Kondo K. 2002. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. Journal of the National Cancer Institute 94:1569-1575.
156. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H. 1999. Suppression of retinal neovascularization by the NF-κB inhibitor pyrrolidine dithiocarbamate in mice. Investigation in Ophthalmology and Visual Science 40:1624-1629.
157. Yoshida SO, Imam A. 1989. Monoclonal antibody to a proximal nephrogenic renal antigen: immunohistochemical analysis of formalin-fixed, paraffin-embedded human renal cell carcinomas. Cancer Research 49:1802-1809.
158. Zhang X, Takenaka I. 2000. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology 56:510-515.
159. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. 2004. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651-655.
160. Zippe C, Pandrangi L, Agarwal A. 1999. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. Journal of Urology 161:62-65.